论文部分内容阅读
达巴万星(dalbavancin)是Durata公司研发的一种新型抗菌素,商品名为Dalvance,于2014年5月23日获FDA批准在美国上市[1],用于治疗成人复杂性急性细菌性皮肤及皮肤结构感染。该药是一种第二代糖肽类抗生素,为静脉注射剂。达巴万星由具有相同母核的A1、A2、B0、B1、B2五个成分组成,其中B0为主要成分。B0游离碱即为道古霉素,中文化学名称:5,31-二氯-38-去(甲氧基羰基)-7-去甲基-
Dalbavancin, a new antibiotic developed by Durata and marketed under the trade name Dalvance, was approved by the FDA on May 23, 2014 for marketing in the United States [1] and is used to treat adults with acute bacterial skin and Skin structure infection. The drug is a second generation of glycopeptide antibiotics, intravenous injection. The dalbavancin is composed of five components A1, A2, B0, B1 and B2 with the same mother nucleus, of which B0 is the main component. B0 free base is the daunorubicin, the Chinese chemical name: 5,31-dichloro-38-to ((methoxycarbonyl) -7-demethyl-